Source comparison
Tesamorelin + Ipamorelin Blend: Dosing & Pathway Comparison
Understanding how tesamorelin + ipamorelin blend compares to individual peptides and alternative secretagogue stacks clarifies why dual-pathway activation produces distinct research outcomes. The table below contrasts receptor targets, typical dosing, GH pulse
This comparison does not assign a generated winner or score.
- Understanding how tesamorelin + ipamorelin blend compares to individual peptides and alternative secretagogue stacks clarifies why dual-pathway activation produces distinct research outcomes. The table below contrasts receptor targets, typical dosing, GH pulse characteristics, and peripheral hormone responses.
- | Peptide / Combination | Primary Receptor Target | Typical Research Dose | GH Pulse Amplitude vs Baseline | Cortisol Elevation | Prolactin Elevation | Half-Life | Bottom Line ||—|—|—|—|—|—|—|| Tesamorelin (monotherapy) | GHRH receptor (GHRHR) | 1–2mg SC daily | 2.5–3.5× baseline | None | None | 26–38 min | Selective GHRH pathway; no ghrelin receptor involvement. Lower peak GH than dual-pathway stacks || Ipamorelin (monotherapy) | GHS-R1a (ghrelin receptor) | 200–300mcg SC daily | 2.0–3.0× baseline | Minimal (<5% elevation) | Minimal (<5% elevation) | 1.5–2 hours | Selective ghrelin mimetic; lacks GHRH synergy. Shorter pulse duration than blends || Tesamorelin + Ipamorelin Blend | GHRHR + GHS-R1a (dual pathway) | 2mg + 200mcg SC daily | 4.0–5.5× baseline | Minimal (<5% elevation) | Minimal (<5% elevation) | 26–38 min (tesamorelin) / 1.5–2 hr (ipamorelin) | Synergistic dual-pathway activation; highest GH amplitude with minimal off-target effects. Gold standard for metabolic research ||